Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NKTR
- Price
- 8.51
- Stock movement up
- +1.05 (3.90%)
- Company name
- Nektar Therapeutics
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 532.52M
- Ent value
- 761.49M
- Price/Sales
- 5.72
- Price/Book
- 10.89
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 2005.26%
- 3 year return
- 81.54%
- 5 year return
- 7.45%
- 10 year return
- 9.79%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NKTR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.72 |
| Price to Book | 10.89 |
| EV to Sales | 8.18 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 19.02M |
| EPS (TTM) | -0.80 |
| FCF per share (TTM) | -0.85 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 93.14M |
| Gross profit (TTM) | 63.15M |
| Operating income (TTM) | -135.94M |
| Net income (TTM) | -168.30M |
| EPS (TTM) | -0.80 |
| EPS (1y forward) | -12.02 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 67.80% |
| Operating margin (TTM) | -145.96% |
| Profit margin (TTM) | -180.70% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.11M |
| Net receivables | 2.12M |
| Total current assets | 286.48M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 28.09M |
| Total assets | 307.97M |
| Accounts payable | 8.58M |
| Short/Current long term debt | 108.26M |
| Total current liabilities | 67.58M |
| Total liabilities | 259.08M |
| Shareholder's equity | 48.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -176.57M |
| Capital expenditures (TTM) | 1.25M |
| Free cash flow (TTM) | -177.81M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -344.29% |
| Return on Assets | -54.65% |
| Return on Invested Capital | -239.10% |
| Cash Return on Invested Capital | -252.62% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 26.95 |
| Daily high | 28.18 |
| Daily low | 26.70 |
| Daily Volume | 816K |
| All-time high | 108.44 |
| 1y analyst estimate | 96.17 |
| Beta | 0.96 |
| EPS (TTM) | -0.80 |
| Dividend per share | - |
| Ex-div date | 11 Jun 2014 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NKTR | S&P500 | |
| Current price drop from All-time high | -74.18% | -1.46% |
| Highest price drop | -99.61% | -56.47% |
| Date of highest drop | 28 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -67.90% | -10.99% |
| Avg time to new high | 80 days | 12 days |
| Max time to new high | 4486 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
532.52M
Marketcap category
Small-cap
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Employees
61
Website
Investor relations
-
SEC filings
CEO
Howard W. Robin
Country
USA
City
San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page